Life Sciences

  • January 23, 2026

    Paraquat, J&J Talc Litigation Headline Philly's 2026 Mass Torts

    Cases concerning illnesses stemming from the herbicide paraquat and talcum power are kicking off 2026 in Philadelphia's mass tort system, pitting corporate powerhouses like Chevron, Syngenta and Johnson & Johnson against the city's perceived plaintiff-friendly juries.

  • January 23, 2026

    Heart Valve Deal Was Blocked Over Innovation Concerns

    The D.C. federal court ruling earlier this month that upended a deal for Edwards Lifesciences Corp. to purchase JenaValve Technology Inc. was based on concerns that the deal would reduce innovation by eliminating competition for a heart valve treatment that's still being developed, according to a ruling unsealed on Friday by the judge who issued it.

  • January 23, 2026

    Cartiva Hid Toe Implant Safety Info, Pa. Woman's Suit Claims

    Cartiva Inc. was sued Thursday in Pennsylvania federal court by a woman who claims that she was injured by a recalled defective toe implant device and that the company has concealed its safety data from regulators and medical providers.

  • January 23, 2026

    $200M Sun, Taro Generics Deal Gets Final OK

    A Pennsylvania federal judge granted final approval Friday for a $200 million deal resolving employee benefits plans' claims against Sun Pharmaceutical and Taro Pharmaceuticals in the sprawling price-fixing litigation against generic-drug makers, while again ensuring the claims from dozens of state attorneys general remain untouched by the settlement.

  • January 23, 2026

    CytoDyn CEO Gets 30-Month Sentence For Lying To Investors

    A lawyer for former CytoDyn CEO Nader Pourhassan — the man convicted in December of securities fraud and insider trading — said that the executive's journey at the company began with a "desire to help people." That journey ended Friday at a hearing in a Maryland federal courtroom with a 30-month prison sentence.

  • January 23, 2026

    New Zynex Leaders Acknowledge Fraud Arrests Of Ex-Execs

    Corporate leaders of bankrupt medical device maker Zynex Inc. said that they were aware of the federal arrests and indictments of the company's former CEO and chief operating officer earlier in the week but that they are no longer employed by the business and have been removed from any position they previously held.

  • January 23, 2026

    3rd Circ. Preview: Citizens Bank, Quest Fight Appeals In Jan.

    The Third Circuit's January lineup will find Citizens Bank and Quest Diagnostics attempting to fight off bids from former employees to revive suits over their compensation.

  • January 23, 2026

    Reforms, $737.5K Fee Proposed To End Del. Skin Tech Suit

    A mediated deal on corporate governance reforms and a fee and expenses award have tentatively settled a consolidated Delaware Court of Chancery derivative suit targeting oversight and disclosure failures involving a "hydrafacial" skin treatment device that cost The Beauty Health Co. at least $63.2 million to manage.

  • January 23, 2026

    Guardant Can Try Again To Nix Patent Tied To $83M Verdict

    The Federal Circuit on Friday threw out a Patent Trial and Appeal Board decision finding Guardant Health couldn't show that a University of Washington DNA sequencing patent is invalid, sending the case back to the board for another look.

  • January 23, 2026

    Taxation With Representation: Vinge, A&O Shearman, Cassels

    In this week's Taxation With Representation, Swedish private equity company EQT buys U.K. secondaries firm Coller Capital, biopharmaceutical giant GSK PLC acquires Rapt Therapeutics Inc., and fusion energy company General Fusion announces plans to go public by merging with special purpose acquisition company Spring Valley Acquisition Corp. III.

  • January 22, 2026

    Patent Office Beats La Jolla Pharma's Application Denial Suit

    A Virginia federal judge on Wednesday upheld a U.S. Patent and Trademark Office decision that denied patent applications from drug developer La Jolla Pharma LLC claiming a unique dosage and delivery method of a drug the company markets to treat low blood pressure, finding the claims are all anticipated or obvious.

  • January 22, 2026

    House Report Claims Evidence of CVS Antitrust Violations

    House Judiciary Committee staffers said Wednesday that they'd uncovered "a pattern of anticompetitive activity" in CVS Health tactics aimed at coercing independent pharmacies into avoiding working with online services the company saw as a threat to its own pharmacy and pharmacy benefit manager businesses.

  • January 22, 2026

    Supplement Cos. Challenge FDA Health Claim Denials

    A group of health supplement companies hit the U.S. Food and Drug Administration with a suit in D.C. federal court Wednesday alleging regulators wrongly denied them approval to make over 100 distinct claims concerning the health benefits of their products.

  • January 22, 2026

    Merck Can't Get Fed. Circ. To Reconsider Axing MS Drug Patents

    The Federal Circuit on Thursday refused to reconsider decisions invalidating Merck KGaA patents on the blockbuster multiple sclerosis drug Mavenclad, turning aside the German drugmaker's claim that the court set an unjust new rule that means inventors' work can later be used against them.

  • January 22, 2026

    Hologic Faces Del. Class Suit Over $18.3B Sale Disclosures

    Citing alleged failures to make news about litigation settlements public ahead of a proposed $18.3 billion company sale, a pension fund stockholder of women's health-focused tech company Hologic Inc. has sued for a Delaware Court of Chancery hold on the deal pending disclosures or damages awards.

  • January 22, 2026

    3rd Circ. Says Medical Pot Contract May Violate Federal Law

    The Third Circuit on Thursday vacated a medical cannabis company's win in a lawsuit filed by a consultant claiming that it had stolen his trade secrets for growing marijuana samples, finding it couldn't decide the appeal because the parties' contract might have violated federal drug law.

  • January 22, 2026

    AI Diagnostics Co.'s Patent Claims Don't Pass Alice Test

    A California federal judge has thrown out artificial intelligence diagnostics company Tempus AI's patent infringement suit against medical test-maker Guardant Health, finding claims in the patents weren't patent-eligible to begin with.

  • January 22, 2026

    Simpson Thacher Adds Quinn Emanuel Atty To New SF Office

    A Quinn Emanuel Urquhart & Sullivan LLP attorney who worked on high-profile intellectual property matters representing Google and Jane Street Group has joined Simpson Thacher & Bartlett LLP as partner in its newly opened San Francisco office, the firm announced Thursday.

  • January 22, 2026

    Medical Cannabis Co. Says Data Breach Didn't Lead To Injury

    An Ohio medical cannabis company has said a consolidated class action in federal court should be dismissed as it doesn't allege any of the plaintiffs' data was accessed in a data breach or that the breach could be linked to any real damage.

  • January 22, 2026

    Investors Drop LA Law Firm From Bioscience Fraud Suit

    A group of investors including a "Toy Story" screenwriter pursuing an $87 million fraud suit against a bioscience company in California state court has agreed to drop claims against a California law firm and its name partner, with the firm in turn withdrawing an anti-SLAPP motion it filed in the suit.

  • January 21, 2026

    Holmes Seeks Trump Clemency For Theranos Fraud Sentence

    Former Theranos CEO Elizabeth Holmes has asked President Donald Trump to commute an 11-year prison sentence she's been serving for defrauding investors with bogus blood-testing technology, according to the U.S. Department of Justice's Office of the Pardon Attorney.

  • January 21, 2026

    CVS, UnitedHealth, Express Scripts Duck PBM Antitrust Suit

    A Missouri federal judge has thrown out a proposed class action accusing the country's three largest pharmacy benefit managers — owned by CVS, UnitedHealth Group and Cigna Group — of inflating prescription costs through their rebating practices.

  • January 21, 2026

    Bristol-Myers' Worker Arbitration Push Scrutinized On Appeal

    A Washington Court of Appeals panel expressed reluctance to award Bristol-Myers Squibb Co.'s bid to send a former worker's age discrimination case to arbitration Wednesday, while also casting some doubt on the ex-employee's stance that the arbitration pact she signed was invalid.

  • January 21, 2026

    Medtronic 'Blocked' Surgical Device Competition, Jury Told

    An executive at Applied Medical Resources Corp. on Tuesday told a California federal jury considering antitrust claims against Medtronic Inc. that a surgical device his company introduced a decade ago had great success in Europe but was "blocked" in the U.S. by Medtronic's practice of "bundling" products.

  • January 21, 2026

    Texas AG Launches Investigation Into Vaccine Incentives

    The Texas attorney general launched what it characterized as a sweeping, multi-industry investigation into financial incentives for medical providers to recommend childhood vaccines, saying providers regularly dish out vaccines that "are not proven to be safe or necessary."

Expert Analysis

  • How 11th Circ.'s Zafirov Decision Could Upend Qui Tam Cases

    Author Photo

    Oral argument before the Eleventh Circuit last month in U.S. ex rel. Zafirov v. Florida Medical Associates suggests that the court may affirm a lower court's opinion that the qui tam provisions of the False Claims Act are unconstitutional — which could wreak havoc on pending and future qui tam cases, say attorneys at Morgan Lewis.

  • Key Trends For Life Sciences Cos. To Watch In 2026

    Author Photo

    Following a year of drastic change at the U.S. Food and Drug Administration, two themes are likely to drive the coming year — a commitment to lowering the cost of drugs and an inherent tension between the priorities of the health agencies and the broader administration, say attorneys at Sheppard Mullin.

  • Series

    Muay Thai Makes Me A Better Lawyer

    Author Photo

    Muay Thai kickboxing has taught me that in order to win, one must stick to one's game plan and adapt under pressure, just as when facing challenges by opposing counsel or judges, says Mark Schork at Feldman Shepherd.

  • The Next Pressure Point In Digital Health: Informed Consent

    Author Photo

    Two new federal digital health initiatives will usher in a new era where virtual care, software-enabled devices and home-based monitoring are integrated into care and reimbursement models, with the impact of shifting rules and opportunities felt most immediately in the context of informed consent, says Kimberly Chew at Husch Blackwell.

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • Trending At The PTAB: The Policies That Are Redefining IPR

    Author Photo

    The evolution of the Patent Trial and Appeal Board's inter partes review institution regime last year, coupled with the policy considerations behind that evolution, marks a shift toward greater gatekeeping of the U.S. Patent and Trademark Office's resources and patent enforcement rights, say attorneys at Finnegan.

  • 4 Trends Shaping Drug And Medical Device Law For 2026

    Author Photo

    2025 saw some significant legal developments with potential impact for drug and device manufacturers, ranging from growing skepticism in science and regulatory entities to new regulation of artificial intelligence, say attorneys at Faegre Drinker.

  • Trending At The PTAB: The Journey Of IPR Institution In 2025

    Author Photo

    Over the course of 2025, inter partes review institution at the Patent Trial and Appeal Board evolved into a more restrictive, policy-driven regime with reshaped discretionary briefing and assessment, and increasing procedural requirements, say attorneys at Finnegan.

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.